London City Equities Limited

LCE

London City Equities Ltd. is a holding company. The company is headquartered in Sydney, New South Wales. The firm is focused on investing in entities that have market shares and offer inherent growth. Its segments include Equity Investment and Other. The company is a selective company-centric investor and not a broad market follower. Its investment strategy is to invest long term in strategic shareholdings in companies, which hold industry positions.

Laserbond Limited

LBL

Laserbond Ltd. engages in the reclamation and surface engineering of industrial components operating in severe environments and critical applications. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-12-17. The firm is focused on the development and application of materials using advanced additive manufacturing technologies. The company specializes in developing technologies and implementing its metal cladding methodologies. The firm operates through three segments: Services, Products, Technology, and Research & Development. The Services segment includes the reclamation or repair of worn components for end users, or the manufacture of products that do not incorporate LaserBond cladding applications. The Products segment is engaged in the manufacture of products incorporating LaserBond cladding applications. The Technology segment is engaged in the sale of LaserBond cladding technology and associated licensing fees and consumables supply. The Research & Development segment includes ongoing development of new or improved technology, applications, and products. The company serves various industries, such as mining, manufacturing, and agriculture.

LBT Innovations Limited

LBT

LBT Innovations Ltd. is an Australian developer of clinical and diagnostic technology, which has emerged as a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefits for busy clinical laboratories. The company is headquartered in Adelaide, South Australia and currently employs 40 full-time employees. The company went IPO on 2006-07-31. Its principal activities includes researching, developing, and commercializing technologies for the healthcare and laboratory supply markets. Its capabilities include artificial intelligence (AI), image analysis and software engineering solutions that improve medical diagnostic workflows. Its Automated Plate Assessment System (APAS) is a platform technology that automates culture-plate screening and interpretation. Its products include APAS Independence and APAS Analysis Modules. The APAS Independence combines AI, software and imaging analysis to create a platform technology for intelligent image interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. Its pipeline includes APAS- antimicrobial resistance (AMR) Analysis Module, Automated Gram Stain Assessment, Biofilm, MicroStreak and WoundVue.